CORDIS
EU research results

CORDIS

English EN
Improving the care of patients suffering from acute or chronic pain

Improving the care of patients suffering from acute or chronic pain

Objective

There is a very high need for improving the management of pain. Acute and persistent pain of different origins represent a common medical, social, and economic burden, and its pharmacotherapy is often inadequate. To advance management of pain patients and support decision making in clinical practice, more predictive assessments of treatment success are needed. The development of analgesics is onerous because promising preclinical data often do not translate into the clinic. Improved pharmacodynamic biomarkers could define whether nociceptive signalling is adequately modulated by a new drug, so increasing the chance of successful translation and greatly reducing the risk in initiating clinical development. Further, the pathophysiology of chronic pelvic pain indications is poorly understood and no adequate preclinical models are available, precluding focused preclinical research and leaving affected patients with little hope of relief.
IMI-PainCare aims at making advances in these three pain areas in a complementary manner. Three subprojects will address specific scientific challenges. Subproject PROMPT will identify Patient Reported Outcome Measures as tools to standardise assessments of treatment success of acute and chronic pain in Real World conditions and controlled trials, and so improve its management; subproject BioPain will validate the translatability of pharmacodynamic biomarkers and PK-PD modelling in pain pathways of healthy subjects and preclinical species, thereby offering tools to improve drug development; subprojectTRiPP will identify biomarkers and novel therapeutic pathways of clinical phenotypes of patients with chronic pelvic pain, which after back-translation, can improve how preclinical models reflecting human diseases.
The goal of IMI-PainCare is to improve the care of patients with acute or chronic pain by providing a toolbox to streamline the development process for novel analgesic drugs and to improve treatment quality in clinical practice.

Coordinator

RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG

Address

Seminarstrasse 2
69117 Heidelberg

Germany

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 823 581,25

Participants (39)

Sort alphabetically

Sort by EU Contribution

Expand all

ACTUAL ANALYTICS LTD

United Kingdom

EU Contribution

€ 114 412,50

AALBORG UNIVERSITET

Denmark

EU Contribution

€ 18 770

AARHUS UNIVERSITET

Denmark

EU Contribution

€ 465 842,50

CHILDREN'S HOSPITAL CORPORATION

United States

EU Contribution

€ 165 667,50

CHRISTIAN-ALBRECHTS-UNIVERSITAET ZU KIEL

Germany

EU Contribution

€ 393 750

CONSULTECH TECHNOLOGIEBERATUNG GMBH

Germany

EU Contribution

€ 435 312,50

EUROPEAN PAIN FEDERATION EFIC

Belgium

EU Contribution

€ 31 250

ENDOMETRIOSIS.ORG LTD

United Kingdom

EU Contribution

€ 7 510

EUROPEAN SOCIETY OF ANAESTHESIOLOGY AISBL

Belgium

EU Contribution

€ 25 000

EUROPEAN SOCIETY OF REGIONAL ANAESTHESIA AND PAIN THERAPY

Switzerland

EU Contribution

€ 25 000

ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS

France

EU Contribution

€ 337 037,50

HELSINGIN JA UUDENMAAN SAIRAANHOITOPIIRIN KUNTAYHTYMÄ

Finland

EU Contribution

€ 201 250

INSTITUTO DE BIOLOGIA MOLECULAR E CELULAR-IBMC

Portugal

EU Contribution

€ 351 901,25

FUNDACION PARA LA INVESTIGACION DEL HOSPITAL CLINICO DE LA COMUNITAT VALENCIANA, FUNDACION INCLIVA

Spain

EU Contribution

€ 257 066,25

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France

EU Contribution

€ 971 328,75

STICHTING INTERNATIONAL PAINFUL BLADDER FOUNDATION

Netherlands

EU Contribution

€ 7 510

KING'S COLLEGE LONDON

United Kingdom

EU Contribution

€ 293 807,50

MRC SYSTEMS GMBH MEDIZINTECHNISCHE SYSTEME

Germany

EU Contribution

€ 144 000

MICHIGAN STATE UNIVERSITY

United States

EU Contribution

€ 29 548,75

NEUROSCIENCE TECHNOLOGIES SLP

Spain

EU Contribution

€ 463 830

PELVIC PAIN SUPPORT NETWORK

United Kingdom

EU Contribution

€ 7 510

PROMPTLY - SOFTWARE SOLUTIONS FOR HEALTH MEASURES, LDA

Portugal

EU Contribution

€ 30 000

QUEEN MARY UNIVERSITY OF LONDON

United Kingdom

EU Contribution

€ 21 483,75

REGION HOVEDSTADEN

Denmark

EU Contribution

€ 57 500

UNIVERSITA DEGLI STUDI DI ROMA LA SAPIENZA

Italy

EU Contribution

€ 442 287,50

UNIVERSITY COLLEGE CORK - NATIONAL UNIVERSITY OF IRELAND, CORK

Ireland

EU Contribution

€ 167 413,75

CLINIQUES UNIVERSITAIRES SAINT-LUC

Belgium

EU Contribution

€ 217 043,75

THE UNIVERSITY OF EDINBURGH

United Kingdom

EU Contribution

€ 288 952,50

Universitätsklinikum Jena

Germany

EU Contribution

€ 1 681 833,75

UNIVERSITE CATHOLIQUE DE LOUVAIN

Belgium

EU Contribution

€ 466 487,50

UNIVERSIDAD DE NAVARRA

Spain

EU Contribution

€ 123 500

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

United Kingdom

EU Contribution

€ 1 494 132,50

WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER

Germany

EU Contribution

€ 663 750

GRUENENTHAL GMBH

Germany

BAYER AKTIENGESELLSCHAFT

Germany

Eli Lilly and Company Limited

United Kingdom

ESTEVE PHARMACEUTICALS, SA

Spain

NOVARTIS PHARMA AG

Switzerland

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

Israel

Project information

Grant agreement ID: 777500

Status

Ongoing project

  • Start date

    1 April 2018

  • End date

    31 March 2022

Funded under:

H2020-EU.3.1.7.

  • Overall budget:

    € 23 355 771,25

  • EU contribution

    € 11 225 271,25

Coordinated by:

RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG

Germany